Key Stats for IQVIA Holdings Stock
- This-Week Performance: -19%
- 52-Week Range: $135 to $247
- Valuation Model Target Price: $259
- Implied Upside: 38%
Value your favorite stocks like IQVIA Holdings with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
IQVIA Holdings Inc. stock fell about 19% this week, ending near $187 per share, as investors reassessed the company’s earnings outlook following its latest results and a wave of analyst price target revisions. Shares dropped sharply after earnings and remained under pressure through the week, signaling a reset in expectations rather than a brief technical pullback.
The stock moved lower because investors focused on slower near-term margin expansion rather than headline revenue growth.
This week, IQVIA reported Q4 revenue of $4.36 billion, up 10.3% year over year, with adjusted EPS rising 9.6% to $3.42 and R&D Solutions backlog reaching a record $32.7 billion.
Management emphasized continued investment in AI-enabled platforms and data infrastructure, which weighed on near-term profitability expectations despite strong demand trends.
Analyst actions added to the pressure this week. Jefferies cut its price target to $255 from $270 while maintaining a Buy rating, JPMorgan lowered its target to $225 from $255 but kept an Overweight rating.
Citigroup also reduced its target to $200 from $230 while reiterating a Neutral stance. While ratings largely remained intact, the lower targets reflected a more cautious view on profit growth timing, even as implied upside varies meaningfully across firms.
Institutional activity was mixed in recent filings. Thrivent Financial reduced its stake by 21%, while TD Waterhouse Canada cut its position by nearly 99%, trimming exposure following recent volatility.
These moves were partially offset by accumulation elsewhere, including a 2.3% increase from Envestnet Asset Management, with institutional investors continuing to own about 89.6% of the company.
Together, earnings digestion, analyst revisions, and selective institutional repositioning help explain the stock’s sharp decline this week.
See analysts’ growth forecasts and price targets for IQVIA Holdings (It’s free) >>>
Is IQVIA Holdings Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 5.9%
- Operating Margins: 16.5%
- Exit P/E Multiple: 16x
Revenue growth reflects steady, contract-backed demand across IQVIA’s research and analytics businesses rather than a rebound-driven surge.
Multi-year clinical contracts, a record backlog, and recurring data and technology services provide high visibility, allowing revenue to compound even when biotech funding or pharma budgets fluctuate.
Margin performance becomes the more important swing factor over the next year. IQVIA is investing heavily in AI-enabled trial design, patient recruitment, and data platforms, which pressures margins in the near term but increases the long-term value of each engagement by shortening timelines, improving success rates, and deepening client integration.
As these capabilities scale across existing customers, incremental revenue can carry higher profitability without proportional cost growth.
Backlog conversion timing also remains critical. IQVIA enters 2026 with strong contracted demand, and smoother trial starts or fewer client delays would translate directly into stronger earnings quality rather than just reported growth.
A continued mix shift toward higher-value R&D Solutions supports margin stabilization once investment intensity peaks.
Based on these inputs, the valuation model estimates a target price of about $259, implying roughly 38% total upside and an annualized return of about 12% over the next 2.9 years.
At current levels, IQVIA appears undervalued, with future performance driven by margin recovery, AI-enabled productivity gains, and consistent backlog monetization rather than aggressive revenue acceleration.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
